

PT PHAPROS Tbk

Analysts: Agung Iskandar / Niken Indriarsih

Phone/Fax/E-mail: (62-21) 7278 2380 / 7278 2370 / agung.iskandar@pefindo.co.id / niken.indriarsih@pefindo.co.id

CREDIT PROFILE		FINANCIAL HIGHLIGHTS				
		As of/for the year ended	Dec-2017	Dec-2016	Dec-2015	Dec-2014
			(Un-audited)	(Audited)	(Audited)	(Audited)
Corporate Rating	<i>idA-/Stable</i>	Total Adjusted Assets [IDR Bn]	1,172.8	881.0	678.5	637.1
Rated Issues		Total Adjusted Debt [IDR Bn]	232.9	108.6	114.0	120.5
<i>MTN I/2017</i>	<i>idA-</i>	Total Adjusted Equity [IDR Bn]	697.8	618.5	447.6	406.6
Rating Period		Total Sales [IDR Bn]	1,002.1	816.1	691.3	578.1
<i>February 13, 2018 – February 1, 2019</i>		EBITDA [IDR Bn]	205.2	143.0	106.5	83.1
Rating History		Net Income after MI [IDR Bn]	125.4	87.0	63.0	44.9
<i>FEB 2017</i>	<i>idA-/Stable</i>	EBITDA Margin [%]	20.5	17.5	15.4	14.4
<i>AUG 2016</i>	<i>idBBB+/Stable</i>	Adjusted Debt/EBITDA [X]	1.1	0.8	1.1	1.5
		Adjusted Debt/Adjusted Equity [X]	0.3	0.2	0.3	0.3
		FFO/Adjusted Debt [%]	60.4	77.3	57.9	42.7
		EBITDA/IFCCI [X]	12.1	6.7	6.5	5.6
		USD Exchange Rate [IDR/USD]	13,548	13,436	13,795	12,440
<small> FFO = EBITDA – IFCCI + Interest Income – Current Tax Expense EBITDA = Operating Profit + Depreciation Expense + Amortization Expense IFCCI = Gross Interest Expense + Other Financial Charges + Capitalized Interest; (FX Loss not included) MI = Minority Interest The above ratios have been computed based on information from the company and published accounts. Where applicable, some items have been reclassified according to PEFINDO's definitions. </small>						

PEFINDO affirms "idA-" ratings for PT Phapros Tbk and its MTN

PEFINDO has affirmed its "idA-" ratings for PT Phapros Tbk (PHAP) and its Medium Term Notes I/2017. The outlook for the corporate rating is "stable".

An obligor rated idA has a strong capacity to meet its long-term financial commitments relative to that of other Indonesian obligors. However, the obligor is somewhat more susceptible to the adverse effects of changes in circumstances and economic conditions than higher-rated obligors.

The minus (-) sign indicates that a rating is relatively weak within its respective rating category.

The ratings reflect PHAP's well-diversified product portfolio, higher profitability margins compared to the average of several listed pharmaceutical companies, and strong cash flow protection measures. The ratings are constrained by its low market competitiveness compared to its peers, the risks related to e-catalogue project, and the risk of raw material price fluctuations.

The rating could be raised if PHAP consistently achieves more than its revenue and/or EBITDA growth targets and improves its market share in the pharmaceutical industry. We could also consider upgrade the rating if the right issue plan runs smoothly and PHAP consistently maintains its conservative capital structure and strong cash flow protection measures. The rating could be lowered if revenue and/or EBITDA are significantly lower than targeted and/or it incurs substantially more debt than projected. The rating will also be under pressure if it is unable to manage its costs in line with the fluctuations of the rupiah against the US dollar.

PHAP is a pharmaceutical company engaged in the production of over-the-counter (OTC), ethical, and generic medicine, as well as in toll manufacturing. As of December 31, 2017, it was 56.6% owned by PT Rajawali Nusantara Indonesia (Persero) and 43.4% by members of the public, including medical doctors, pharmacists, and other healthcare professionals. Despite its status as a public company, as it is owned by more than 300 shareholders, it is not listed on the Indonesia Stock Exchange.

DISCLAIMER

PT Pemeringkat Efek Indonesia (PEFINDO) does not guarantee the accuracy, completeness, timeliness or availability of the contents of this report or publication. PEFINDO cannot be held liable for its use, its partial use, or its lack of use, in combination with other products or used solely, nor can it be held responsible for the result of its use or lack of its use in any investment or other kind of financial decision making on which this report or publication is based. In no event shall PEFINDO be held liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses including but not limited to lost profits and opportunity costs in connection with any use of the contents of this report or publication. Credit analyses, including ratings, and statements in this report or publication are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities or to make any investment decision. The contents cannot be a substitute for the skill, judgment and experience of its users, its management employees and/or clients in making investment or other business decisions. PEFINDO also assumes no obligation to update the content following publication in any form. PEFINDO does not act as fiduciary or an investment advisor. While PEFINDO has obtained information from sources it believes to be reliable, PEFINDO does not perform an audit and does not undertake due diligence or independent verification of any information used as the basis of and presented in this report or publication. PEFINDO keeps the activities of its analytical units separate from its business units to preserve independence and objectivity of its analytical processes and products. As a result, certain units of PEFINDO may have information that is not available to other units. PEFINDO has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. PEFINDO may receive compensation for its ratings and other analytical work, normally from issuers of securities. PEFINDO reserves the right to disseminate its opinions and analyses. PEFINDO's public ratings and analyses are made available on its website, <http://www.pefindo.com> (free of charge) and through other subscription-based services, and may be distributed through other means, including via PEFINDO publications and third party redistributors. Information in PEFINDO's website and its use fall under the restrictions and disclaimer stated above. Reproduction of the content of this report, in full or in part, is subject to written approval from PEFINDO.